Although a pilot study in patients with focal DRE suggested that HMGB1 may be a candidate biomarker in epilepsy (Walker et al., 2016), HMGB1 is not specific to epileptic process; it’s presence has been associated with autoimmune and malignant diseases (Pilzweger and Holdenrieder, 2015). Here, HMGB1 is linked to epilepsy.